PDF herunterladen
CC BY-NC-ND 4.0 · South Asian J Cancer 2019; 08(03): 159-165
DOI: 10.4103/sajc.sajc_18_19
Letter to the Editor

An exceptional response to nivolumab in relapsed and refractory malignant mesothelioma

Vikas T. Talreja
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, Indiai
,
Vanita Noronha
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, Indiai
,
Amit Joshi
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, Indiai
,
Vijay Patil
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, Indiai
,
Abhishek Mahajan
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, Indiai
,
Kumar Prabhash
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, Indiai
› Institutsangaben Financial support and sponsorship Nil.
› Weitere Informationen
Auch verfügbar auf
  als PDF herunterladen Lizenzen und Reprints


Publikationsverlauf

Artikel online veröffentlicht:
21. Dezember 2020

© 2019. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Delgermaa V, Takahashi K, Park EK, Le GV, Hara T, Sorahan T, et al. Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bull World Health Organ 2011;89:716-24, 724A-724C.
  • 2 Zucali PA, Ceresoli GL, Garassino I, De Vincenzo F, Cavina R, Campagnoli E, et al. Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. Cancer 2008;112:1555-61.
  • 3 Quispel-Janssen J. OA13.01 a phase II study of nivolumab in malignant pleural mesothelioma (NivoMes): With translational research (TR) biopies. J Thoracic Oncol 2017;12:S292-3.
  • 4 Available from: https://www.eortc.be/services/doc/ctc/CTCAE_4.032010-06-14_QuickReference_5x7.pdf. [Last accessed on 2018 Dec 12].